Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 87,500 shares of the business’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $17.06, for a total transaction of $1,492,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Howard W. Robin also recently made the following trade(s):

  • On Thursday, September 1st, Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.83, for a total transaction of $1,560,125.00.
  • On Tuesday, August 16th, Howard W. Robin sold 11,817 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.56, for a total transaction of $207,506.52.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 17.00 on Friday. The stock’s market cap is $2.32 billion. Nektar Therapeutics has a 1-year low of $9.92 and a 1-year high of $19.98. The company’s 50-day moving average is $18.17 and its 200-day moving average is $15.89.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 68.30%. The business had revenue of $32.77 million for the quarter, compared to analysts’ expectations of $34.17 million. During the same period in the prior year, the business posted ($0.40) earnings per share. The business’s quarterly revenue was up 44.6% compared to the same quarter last year. Equities analysts expect that Nektar Therapeutics will post ($1.11) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Several equities analysts have recently commented on NKTR shares. Brean Capital reissued a “buy” rating and issued a $23.00 target price on shares of Nektar Therapeutics in a report on Friday, September 30th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 26th. Jefferies Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $21.00 target price (up previously from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.75.

A number of institutional investors have recently bought and sold shares of NKTR. Primecap Management Co. CA raised its position in Nektar Therapeutics by 1.1% in the first quarter. Primecap Management Co. CA now owns 20,010,086 shares of the biopharmaceutical company’s stock worth $275,139,000 after buying an additional 225,800 shares in the last quarter. Vanguard Group Inc. raised its position in Nektar Therapeutics by 2.7% in the second quarter. Vanguard Group Inc. now owns 11,650,468 shares of the biopharmaceutical company’s stock worth $165,787,000 after buying an additional 301,245 shares in the last quarter. BlackRock Fund Advisors raised its position in Nektar Therapeutics by 1.9% in the second quarter. BlackRock Fund Advisors now owns 10,221,478 shares of the biopharmaceutical company’s stock worth $145,452,000 after buying an additional 192,003 shares in the last quarter. Bridger Management LLC purchased a new stake in shares of Nektar Therapeutics during the first quarter worth approximately $48,359,000. Finally, State Street Corp boosted its stake in shares of Nektar Therapeutics by 4.5% in the first quarter. State Street Corp now owns 3,480,120 shares of the biopharmaceutical company’s stock worth $47,852,000 after buying an additional 151,371 shares during the last quarter. 96.91% of the stock is owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.